tbuckley/cabot-search huggingface dataset:
Discovery of Human-Similar Gene Fusions in Canine Cancers
Authors: Ronan Ulvé, Mélanie Rault, Mathieu Bahin, Laetitia Lagoutte, Jérôme Abadie, Clotilde De Brito, Jean-Michel Coindre, Nadine Botherel, Audrey Rousseau, Valentin Wucher, Edouard Cadieu, Catherine Thieblemont, Christophe Hitte, Laurence Cornevin, Florian Cabillic, Laura Bachelot, David Gilot, Benoit Hennuy, Thierry Guillaudeux, Arnaud Le Goff, Thomas Derrien, Benoît Hédan, Catherine André
Journal: Cancer Research (2017)

Abstract Canine cancers represent a tremendous natural resource due to their incidence and striking similarities to human cancers, sharing similar clinical and pathologic features as well as oncogenic events, including identical somatic mutations. Considering the importance of gene fusions as driver alterations, we explored their relevance in canine cancers. We focused on three distinct human-comparable canine cancers representing different tissues and embryonic origins. Through RNA-Seq, we discovered similar gene fusions as those found in their human counterparts: IGK-CCND3 in B-cell lymphoma, MPB-BRAF in glioma, and COL3A1-PDGFB in dermatofibrosarcoma protuberans-like. We showed not only similar partner genes but also identical breakpoints leading to oncogene overexpression. This study demonstrates similar gene fusion partners and mechanisms in human–dog corresponding tumors and allows for selection of targeted therapies in preclinical and clinical trials with pet dogs prior to human trials, within the framework of personalized medicine. Cancer Res; 77(21); 5721–7. ©2017 AACR.
標的乳癌イメージングのための超音波造影剤としてのニューロペプチドY Y_1受容体を介した生分解性光ルミネセンスナノバブル【Powered by NICT】
Authors: Li Juan, Tian Yuchen, Shan Dingying, Gong An, Zeng Leyong, Ren Wenzhi, Xiang Lingchao, Gerhard Ethan, Zhao Jinshun, Yang Jian, Wu Aiguo
Journal: Biomaterials (2017)
Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study
Authors: Florent Malard, Myriam Labopin, Ibrahim Yakoub-Agha, Sylvain Chantepie, Thierry Guillaume, Didier Blaise, Reza Tabrizi, Leonardo Magro, Bernard Vanhove, Gilles Blancho, Philippe Moreau, Béatrice Gaugler, Patrice Chevallier, Mohamad Mohty
Journal: Blood (2017)
in situリモデリングと急速な骨再生ナノ粒子媒介生体模倣フィトロッカイト無機【Powered by NICT】
Authors: D Kim Hwan, Jang Hae Lin, Ahn Hyo-Yong, Lee Hye Kyoung, Park Jungha, Lee Eun-seo, A Lee Eunjee, Jeong Yong-Hoon, Kim Do-Gyoon, Nam Ki Tae, S Hwang Nathaniel
Journal: Biomaterials (2017)
Do patients at risk of infective endocarditis need antibiotics before dental procedures?
Authors: Thomas J Cahill, Mark Dayer, Bernard Prendergast, Martin Thornhill
Journal: BMJ (2017)

#### What you need to know

Infective endocarditis is a life threatening disease with 30% one year mortality1 that affects 3-10 per 100 000 population per year—the average general practitioner will see one case every 20 years.2 Infective endocarditis occurs when bacteria enter the bloodstream through the mouth, gut, or skin, and replicate within the heart to form a “vegetation,” which is usually adherent to one of the valves (fig 1⇓, fig 2⇓). Specific patient subgroups are at increased risk of infective endocarditis as a result of damaged cardiac endothelium, abnormal blood flow, intracardiac prosthetic material, immunosuppression, or recurrent bacteraemia (box 1).3 4



Fig 1 Pathogenesis of infective endocarditis





Fig 2 Infective endocarditis. Vegetation can be seen on the mitral valve (arrow)



#### Box 1: Risk factors for infective endocarditis

##### Cardiac

##### Non-cardiac

Streptococci which colonise the mouth are the causative organism in …
関節炎治療のためのsiRNAとデキサメタゾンを共送達する高分子ハイブリッドミセルによるNF‐κBシグナル伝達の標的化【Powered by NICT】
Authors: Wang Qin, Jiang Hao, Li Yan, Chen Wenfei, Li Hanmei, Peng Ke, Zhang Zhirong, Sun Xun
Journal: Biomaterials (2017)
SAT0154 Effectiveness and safety of CT-P13 in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis: observational study in republic of korea
Authors: D-W Kim, T-H Kim, SR Kwon, EY Lee, C-N Son, YS Kim, SH Kim, Y-B Park, J-W Hur, H-S Lee, SJ Lee, SH Lee
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> CT-P13 is approved as a biosimilar of innovator infliximab for marketing in 79 countries around the world. After approval, observational study has been conducted in Republic of Korea in patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) and Plaque Psoriasis (PS). <h3>Objectives</h3> To evaluate the effectiveness and safety of CT-P13 under routine care in Republic of Korea. <h3>Methods</h3> This observational study included both biologic naïve patients (Naïve group) and patients who switched from other anti-tumor necrosis factor (TNF)s to CT-P13 (Switch group). Effectiveness were evaluated based on remission (DAS28≤2.6 in RA, BASDAI&lt;3 in AS and absence of swollen and tender joint counts in PsA), and response (BASDAI 20/50/70 in AS and PASI 50/75 in PS). Adverse events (AEs) were collected over 6 month period. <h3>Results</h3> Total 940 patients (400 with RA, 531 with AS, 3 with PsA and 6 with PS) were registered and 338 (36.0%) patients (108 with RA, 228 with AS, 2 with PS) who switched to CT-P13 were included. The proportion of patients achieving remission was similar between Naïve and Switch groups in both RA and AS during post-baseline visits (Table 1). In RA, the proportion of patients achieving each disease activity category by DAS28 was similar between Naïve and Switch groups (Figure 1). The proportion of patients who achieved BASDAI 20/50/70 response gradually increased from week 6 to week 24 or 30 in Naïve group with AS (Figure 1). Fifty percent of naïve patients with PsA achieved clinical remission. The proportions of both PASI 50 and 75 responses were 50% at Week 22 in Naïve group and were 100% and 50% in Switch group, respectively during post-baseline visits in PS patients. Throughout this study, treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events (TESAE) were reported as Table 2. Only 11% of patients experienced infection. <h3>Conclusions</h3> CT-P13 is efficacious and well-tolerated in RA/AS/PsA/PS patients. Efficacy and safety results in patients treated with CT-P13 were clinically consistent to historical data [1,2,3]. Especially, Switch group results showed that CT-P13 provides a useful alternative to other anti-TNFs. <h3>References</h3> Kobayashi et al (2016). Hetland et al (2005). Hetland et al (2010). <h3>Disclosure of Interest</h3> D.-W. Kim: None declared, T.-H. Kim: None declared, S. R. Kwon: None declared, E. Y. Lee: None declared, C.-N. Son: None declared, Y. S. Kim: None declared, S. H. Kim: None declared, Y.-B. Park: None declared, J.-W. Hur: None declared, H.-S. Lee: None declared, S. J. Lee Employee of: CELLTRION,Inc., S. H. Lee Employee of: CELLTRION,Inc.
Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutide
Authors: Owen Dyer
Journal: BMJ (2017)

The Danish drug company Novo Nordisk has paid $58.7m (£45m; €49m) to settle a cluster of seven US lawsuits accusing the company of deceptive sales practices, paying kickbacks to high prescribing doctors, and playing down the cancer risks of its best selling antidiabetes drug liraglutide (marketed as Victoza).

The company was accused of promoting the off-label use of liraglutide in patients who did not have type 2 diabetes, of paying kickbacks to doctors, and of disguising its sales staff as “diabetes educators” before sending them to doctors’ offices.

But the most serious allegations concerned the company’s …
Influenza vaccination: policy versus evidence
Authors: Peter Doshi
Journal: BMJ (2006)

In his review of the available literature, Jefferson finds a large gap between influenza vaccination policy and what the data tell us.1 What the data tell us, he writes, is that the inactivated vaccines have little or no effect on the effects measured, and the comparative evidence is insufficient to demonstrate the vaccines are safe. 

Jefferson's results are consistent with previous epidemiological …
The Tanenbaum Open Science Institute: Leading a Paradigm Shift at the Montreal Neurological Institute
Authors: Viviane Poupon, Annabel Seyller, Guy A. Rouleau
Journal: Neuron (2017)

The Montreal Neurological Institute is adopting an Open Science Policy that will be enacted by the Tanenbaum Open Science Institute. The aim is to accelerate the generation of knowledge and novel effective treatments for brain disorders by freeing science.
Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease
Authors: Raj Vuppalanchi, Mohammad S. Siddiqui, Mark L. Van Natta, Erin Hallinan, Danielle Brandman, Kris Kowdley, Brent A. Neuschwander‐Tetri, Rohit Loomba, Srinivas Dasarathy, Manal Abdelmalek, Edward Doo, James A. Tonascia, David E. Kleiner, Arun J. Sanyal, Naga Chalasani
Journal: Hepatology (2017)

Vibration‐controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive assessments of hepatic fibrosis and steatosis, respectively. However, prior vibration‐controlled transient elastography studies reported high failure rates in patients with nonalcoholic fatty liver disease. We examined the performance characteristics of the FibroScan 502 Touch with two probes, medium (M+) and extra large (XL+), in patients with nonalcoholic fatty liver disease in a multicenter setting. A total of 1,696 exams were attempted in 992 patients (body mass index, 33.6 ± 6.5 kg/m 2 ) with histologically confirmed nonalcoholic fatty liver disease. Simultaneous assessment of LSM and CAP was performed using the FibroScan 502 Touch with an automatic probe selection tool. Testing was conducted twice in patients by either a single operator (87%) or two operators (13%). Failure was defined as the inability to obtain a valid examination. An examination was considered unreliable if LSM interquartile range/median was &gt;30%. Significant disagreement between two readings was defined as &gt;95% limits of agreement between two readings. A total of 1,641 examinations yielded valid results with a failure rate of 3.2% (55/1,696). The proportion of unreliable scans for LSM was 3.9%. The proportion of unreliable scans with operator experience in the top quartile (≥59 procedures) was significantly lower than that in the lower three quarters combined (1.6% versus 4.7%, P = 0.02 by Fisher's exact test). The significant disagreement between first and second readings for LSM and CAP when obtained back to back was 18% and 11%, respectively. Conclusion: Vibration‐controlled transient elastography for estimation of LSM and CAP can be successfully deployed in a multicenter setting with low failure (3.2%) and high reliability (&gt;95%) rates and high reproducibility. (H epatology 2018;67:134‐144).
Abstract 13033: Abnormal P-Wave Axis is Associated With an Increased Risk of Sudden Cardiac Death: The Atherosclerosis Risk In Communities (ARIC) Study
Authors: Ankit Maheshwari, Faye L Norby, Wesley T O’Neal, Selcuck Adabag, Alvaro Alonso, Elsayed Z Soliman, Lin Y Chen
Journal: Circulation (2016)

Introduction: Abnormal P-wave axis (aPWA) has been linked to all-cause mortality and incident atrial fibrillation (AF). The relationship between aPWA and sudden cardiac death (SCD), however, has not been defined. Hypothesis: We hypothesized that aPWA is independently associated with SCD and tested our hypothesis in the ARIC study, a community-based prospective cohort study. Methods: We included 15,381 participants (age 54.2 ± 5.7 years, 55% women, 26.4% blacks) who attended the baseline visit (1987-89) and with complete ECG data. aPWA was defined as any value outside 0-75 degrees using 12-lead ECGs obtained during the baseline exam. SCD was physician-adjudicated and defined as a sudden, pulseless condition in a previously stable individual without evidence of a non-cardiac cause of death. Cox regression was used to compute hazard ratios and 95% confidence intervals for the association of aPWA with SCD. Results: At baseline, there were 1,275 participants with aPWA. During a mean follow-up of 13.1 years (1987-2001), 272 SCDs were identified from coronary heart disease deaths. aPWA was associated with a 1.49-fold (95% CI, 1.03-2.15) increased risk of SCD independent of traditional SCD risk factors. However, after adjustment for time-dependent AF, the association of aPWA with SCD was attenuated (Table). Conclusions: aPWA is associated with an increased risk of SCD in the general population. This association, however, is likely mediated by AF; the latter we recently reported to be a risk factor for SCD. aPWA is associated with an increased risk of SCD in the general population. This association, however, is likely mediated by AF; the latter we recently reported to be a risk factor for SCD.
6 クロマノール誘導体SUL CIXは脂肪組織由来幹細胞の長期低温保存を可能にする【Powered by NICT】
Authors: Hajmousa Ghazaleh, Vogelaar Pieter, A Brouwer Linda, C van der Graaf Adrianus, H Henning Robert, Krenning Guido
Journal: Biomaterials (2017)
慢性脊髄半側切断ラットにおけるグラフェン酸化物足場により誘導される免疫調節と血管新生反応【Powered by NICT】
Authors: Lopez-Dolado Elisa, Gonzalez-Mayorga Ankor, Gutierrez Maria Concepcion, Serrano Maria Concepcion
Journal: Biomaterials (2016)
All tests can sometimes cause more harm than good
Authors: Jessica C Watson
Journal: BMJ (2017)

Hofmann and Welch warn of the downsides of diagnostic tests.1 “All screening programmes do harm . . . [but] some do more good than harm at a reasonable cost.”2 This provocative statement is arguably true of any test, not just screening or new diagnostic tests. The challenge for clinicians is to share decisions with patients—choosing the right test for the right patient at the right time.

Inflammatory marker tests, such as C reactive protein, …
Acquired erythropoietic uroporphyria secondary to myelodysplastic syndrome with chromosome 3 alterations: a case report
Authors: S. Podlipnik, F. Guijarro, A. Combalia, J. To-Figueras, C. Badenas, D. Costa, M. Rozman, S. Jorge, P. Aguilera, A. Gaya
Journal: British Journal of Dermatology (2017)

Congenital erythropoietic porphyria is a rare autosomal recessive disease caused by a deficiency of uroporphyrinogen III synthase, owing to mutations in UROS in chromosome 10. Occasionally, patients show a mild, late‐onset disease, without germline UROS mutations, associated with haematological malignancies. We report a 65‐year‐old patient with photosensitivity, overexcretion of porphyrins and thrombocytopenia. Bone marrow analysis gave a diagnosis of myelodysplastic syndrome (MDS) with the presence of a derivative chromosome 3, possibly due to an inversion including 3q21 and 3q26 break points. After allogeneic stem‐cell transplantation, complete remission of MDS and uroporphyria was achieved. To our knowledge, this is the first reported case of acquired erythropoietic uroporphyria associated with MDS, with chromosome 3 alterations.
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study)
Authors: Lingyun Zhang, Xiujuan Qu, Yuee Teng, Jing Shi, Ping Yu, Tao Sun, Jingyan Wang, Zhitu Zhu, Xiuna Zhang, Mingfang Zhao, Jing Liu, Bo Jin, Ying Luo, Zan Teng, Yuyang Dong, Fugang Wen, Yuzhi An, Caijun Yuan, Tiejun Chen, Lizhong Zhou, Ying Chen, Jian Zhang, Zhenghua Wang, Jinglei Qu, Feng Jin, Jingdong Zhang, Xiuhua Jin, Xiaodong Xie, Jun Wang, Li Man, Lingyu Fu, Yunpeng Liu
Journal: Journal of Clinical Oncology (2017)

Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC). Patients and Methods In a randomized, double-blind, active-controlled, phase III trial, chemotherapy-naive patients with cancer who were scheduled to receive HEC that contained cisplatin or cyclophosphamide-doxorubicin/epirubincin ≥ 50 mg/m2 regimens were randomly assigned to a THD group (100 mg twice daily on days 1 to 5) or placebo group, both with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4). Primary end point was complete response to vomiting-no emesis or use of rescue medication-in the delayed phase (25 to 120 h). Nausea and anorexia on days 1 to 5 were evaluated by the 4-point Likert scale (0, no symptoms; 3, severe). Quality of life was assessed by the European Organization for Research and Treatment of Cancer QLQ-C30 version 3 questionnaire on days -1 and 6. Results Of 656 patients, 638 were evaluable: 317 in the THD group and 321 in the control group. Compared with placebo, delayed and overall (0 to 120 h) complete response rates to vomiting were significantly higher with THD: 76.9% versus 61.7% ( P < .001) and 66.1% versus 53.3% ( P = .001), respectively. Rates of no nausea were also higher in the THD group (delayed: 47.3% v 33.3%; P < .001; overall: 41% v 29.6%; P = .003), and mean scores of anorexia were lower overall (0.44 ± 0.717 v 0.64 ± 0.844; P = .003). Adverse effects were mild to moderate. The THD group had increased sedation, dizziness, constipation, and dry mouth, but experienced better quality of life after chemotherapy. Conclusion Thalidomide combined with palonosetron and dexamethasone significantly improved HEC-induced delayed nausea and vomiting prevention in chemotherapy-naive patients.
Validity of Surrogate End Points for Prostate Cancer
Authors: Stuart G. Baker
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A New Chapter for Diabetic Kidney Disease
Authors: Ian H de Boer
Journal: New England Journal of Medicine (2017)

Many clinical outcomes have improved over the past two decades for people living with diabetes.1 However, relatively little progress has been made in the treatment of diabetic kidney disease. Among adults with diabetes in the United States, the prevalence of diabetic kidney disease has remained steady, near 26%,2 and, depending on the data source, rates of end-stage renal disease (ESRD) have either remained stable or decreased only slightly.1 Why has diabetic kidney disease proved so difficult to prevent and treat? In part, the successes of preventing atherosclerotic complications and prolonging life mean that people with diabetes are exposed to longer . . .
Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
Authors: Evangelia Vlachodimitropoulou, Yu-Lin Chen, Maciej Garbowski, Pimpisid Koonyosying, Bethan Psaila, Martha Sola-Visner, Nichola Cooper, Robert Hider, John Porter
Journal: Blood (2017)
Prognostic Impact of Pedal Artery Angioplasty for Critical Limb Ischemia Patients with Pedal Artery Diseases: Result from RENDEZVOUS Registry
Authors: Nakama Tatsuya, Watanabe Nozomi, Haraguchi Takuya, Sakamoto Hiroshi, Kamoi Daisuke, Tsubakimoto Yoshinori, Ogata Kenji, Satoh Katsuhiko, Urasawa Kazushi, Andoh Hiroshi, Fujita Hiroshi, Shibata Yoshisato
Journal: Circulation (2016)
3D冠内超音波(3D‐ICUS)によって評価した「ステント辺縁部効果」およびステント内再狭窄(ISR)
Authors: Shinjo H, Ozaki Y, Yasukawa T, Kakihana M, Waseda K, Kuroda Y, Wakita Y, Asai K, Itoh T
Journal: Circulation (2003)
A Randomized Controlled Trial of an Additional Funding Intervention to Improve Clinical Trial Enrollment
Authors: Catriona Parker, Raymond Snyder, Michael Jefford, David Dilts, Rory Wolfe, Jeremy Millar
Journal: Journal of the National Comprehensive Cancer Network (2017)

Background: A low proportion of adults with cancer are recruited to clinical trials. Cancer Council Victoria provides funding to clinical trial sites through its statewide Cancer Trials Management Scheme (CTMS). Historically, there appeared to be a relationship between budget-allocated funding and the number of patients recruited. A randomized controlled trial was conducted to test whether additional funding in 2013 would increase trial recruitment. Methods: A total of 18 trial centers ("sites") received usual CTMS funds, whereas 16 intervention sites received usual funds plus additional funds, proportional to recruitment in 2011; additional payments to sites in the intervention group ranged from $6,750 to $234,000 AUD (≈$6,750–$234,000 USD at the time). This represented an average 11.8% (interquartile range [IQR], 8.0%, 12.3%) increase in sites' budgets. Sites were required to use the funds with the aim of increasing recruitment. The study end point was the number of new participants recruited to trials in 2013. An online survey assessed strategies used to increase recruitment. Results: The median number of new trial recruits per site in 2013 was 21 (IQR, 5–39) in the control arm and 12.5 (IQR, 3.5–44.5) in the intervention arm. The ratio of new trial recruitment numbers at the intervention sites compared with control sites in 2013, adjusting for respective 2012 numbers and institution type, was 0.99 (95% CI, 0.69, 1.43; P=.96). The survey revealed most intervention sites used funding to increase staffing. Conclusions: Additional funding at a site level did not lead to a contemporaneous increase in trial recruitment.